Multicenter retrospective study for brain metastases from breast cancer: Impact of molecular subtype on clinical outcomes
Not Applicable
- Conditions
- brain metastases
- Registration Number
- JPRN-UMIN000027908
- Lead Sponsor
- Japanese Gamma Knife Society
- Brief Summary
The breast cancer subtype was Luminal in 155 patients, Luminal-HER2 in 110, HER2 in 105, and triple negative (TN) in 69. The median overall survival time (months) after GKS was 10.4 in TN, 13.7 in Luminal, 31.4 in HER2 and 35.8 in Luminal-HER2. The cumulative incidence of SD and ND at 5 years after GKS was 69.3% and 9.8%, respectively. HER2-positive patients including HER2 and Luminal-HER2 had lower incidences in SD and ND but higher local recurrence incidence compared to HER2-negative patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 439
Inclusion Criteria
Not provided
Exclusion Criteria
patients with undetermined genetic phenotype
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method oss of functional independence Neurological death
- Secondary Outcome Measures
Name Time Method Overall survival, tumor control, tumor recurrence, radiation injury, distant recurrence